Cooperative Agreement UG3CA305707
Award Date 9/12/25
Completion Date 8/31/27
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
- This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to facilitate the scale-up and sustainment of high-quality lung cancer screening using the QUILS system. The $1,549,462 award, effective September 8, 2025 through August 31, 2027, supports the evaluation of the QUILS system 2.0 in 60 lung cancer screening programs to improve implementation and achieve higher screening rates. The...
- The National Cancer Institute awarded a $1,593,217 Cooperative Agreement to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The objective of this I-LEARN study is to compare the effectiveness of different selection approaches and tailoring of implementation strategies to increase the scale and sustainment of high-quality lung cancer...
- This federal Cooperative Agreement award is from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The $1,594,797 award supports a project to evaluate strategies for scaling up and sustaining tobacco use treatment (TUT) in cancer survivors across a network of 72 clinics. The project aims to adapt and refine implementation strategies, harmonize outcome measures, and establish the feasibility of a multi-stage...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- This $658,743 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Kaiser Foundation Hospitals aims to develop and validate prediction models for trajectories of function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer during up to 6 months of chemotherapy and/or immunotherapy. The 5-year project builds on an ongoing observational cohort study of 130 older adults with advanced lung...
- The National Cancer Institute awarded a $621,406 Project Grant to the Fred Hutchinson Cancer Center (also known as the Seattle Cancer Care Alliance) under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) federal grant program. The grant, with a performance period from August 1, 2025 to July 31, 2030, will fund a multilevel intervention to improve follow-up colonoscopy rates among patients receiving colorectal cancer screening through fecal immunochemical tests (FIT) in...
- This Project Grant award of $1,131,820.00 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports research to characterize toxicities and health-related quality of life outcomes among a diverse sample of 416 individuals receiving immune checkpoint inhibitor treatment for metastatic cancer. The study aims to examine associations between patient sociodemographic/medical factors and symptomatic toxicities and quality of...
- This federal Project Grant award of $429,399 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund research to "RECALIBRATE THE LUNG CANCER POLICY MODEL (LCPM) TO ADDRESS LUNG CANCER RISK AND LUNG CANCER SCREENING PRACTICES IN REAL-WORLD POPULATIONS." The goal is to improve the LCPM's accuracy in estimating the health and economic impacts of low-dose computed tomography (LDCT) lung cancer screening by 1) adjusting the model to reflect...
- This Cooperative Agreement award for $703,321.00, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393), will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors. The project aims to improve coordination of care, including surveillance for cancer recurrence, management of long-term effects, and delivery of preventive and...
- This Project Grant award, totaling $158,365, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to understand the impact of NRF2 activation on the initiation and progression of lung squamous cell carcinoma (LUSC). The primary awardee, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to test how an activated NRF2 mutation affects LUSC incidence, tumor...